Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
NVE Corporation Q2 Fiscal 2026 Earnings Call - Sequential Revenue Uptick; In-House Chip-Scale Packaging Poised to Fuel Growth
NVE reported a modest but meaningful sequential revenue rise of 4% for the quarter ended September 30, 2025, even as revenue declined 6% year over year. The swing came from product sales holding rough...
- Revenue rose 4% sequentially but fell 6% year over year for the quarter ended Sept 30, 2025.
- Product sales were essentially flat year over year, up 1%, driven by a 21% increase in non-defense sales and offset by a 64% drop in defense product sales.
- Contract R&D revenue collapsed 68% year over year and now represents about 3% of total revenue, underscoring the lumpy nature of government contracts.
- +13 more takeaways
LendingClub Q3 2025 Earnings Call - Balance-sheet-backed marketplace growth and disciplined underwriting fuel record recurring revenue and tripled EPS
LendingClub posted a clean, accelerating quarter: originations jumped 37% to $2.62 billion, revenue rose 32% to $266 million, and diluted EPS nearly tripled to $0.37. Management argues the story is no...
- Originations rose 37% year over year to $2.62 billion, beating guidance and marking the highest quarterly originations in three years.
- Total revenue grew 32% to $266 million, driven by a 75% jump in non-interest income to $108 million and record net interest income of $158 million.
- Net interest margin expanded to 6.2%, supporting the highest-ever net interest income and reinforcing the thesis that a bank balance sheet is a durable competitive advantage.
- +12 more takeaways
Ategrity Q3 2025 Earnings Call - 30% GWP and 88.7% Combined Ratio as Tech-Enabled Underwriting Drives Share Gains
Ategrity delivered a punchy quarter: gross written premiums rose 30% year over year, submissions surged more than 70%, and adjusted net income jumped to $22.8 million, up 78% from last year. The compa...
- Record top-line and earnings: Gross written premiums up 30% YoY, submissions +70% YoY, adjusted net income $22.8 million (+78% YoY).
- Improved underwriting profitability: Combined ratio improved to 88.7% from 95.3% a year ago; underwriting income $10.6 million, up ~208% YoY.
- Loss activity and reserving: Loss ratio declined to 60% (down 2.1 pts); no prior year development this quarter versus 1.7 pts last year; catastrophe losses were 4% of NEP versus 12.1% last year.
- +12 more takeaways
Knight-Swift Transportation Holdings Inc. Third Quarter 2025 Earnings Call - Cautious Q4 Guidance as Regulatory Enforcement Could Tighten Capacity into 2026
Knight-Swift closed Q3 with mixed operational traction and a cautious tone for the back half of the year. GAAP results were weighed down by $58 million of unusual items, but underlying adjusted operat...
- GAAP results included $58 million of unusual items: $28.8 million trade name impairment, $6 million property/software impairments, $11.2 million loss contingency tied to the 2024 exit from third-party carrier insurance, and $12 million of US Xpress auto liability claim settlements.
- Adjusted EPS was $0.32 in Q3 2025, down modestly from $0.34 a year earlier after a $0.10 negative impact from the insurance loss contingency and US Xpress claims; GAAP EPS was $0.05 versus $0.19 a year ago.
- Revenue excluding fuel surcharge rose 2.4% year over year, while consolidated adjusted operating income improved 14.2% year over year after adjusting for impairments.
- +12 more takeaways
QuantumScape Q3 2025 Earnings Call - Ducati Demo, QSC5 B1 Shipments and First Customer Billings Signal Commercial Momentum
QuantumScape used Q3 to convert technical milestones into visible commercial steps. The company shipped Cobra-based QSC5 B1 cell samples and staged a high-profile field demonstration with Volkswagen G...
- Ducati V21L public demo at IAA Mobility was the company’s first live demonstration of QS solid-state lithium metal batteries, intended as a high-visibility, low-volume launch program and now moving to field testing.
- QuantumScape began shipping Cobra-based QSC5 B1 cell samples in Q3, completing one of its stated 2025 operational goals.
- The Eagle Line pilot line in San Jose has had certain key assembly equipment installed, and the company says higher-volume pilot equipment installation remains on track.
- +12 more takeaways
Ribbon Communications Q3 2025 Earnings Call - Assumes U.S. Federal Purchases Delayed to 2026, While AI and Cloud Wins Fuel Longer-Term Upside
Ribbon reported a steady Q3, $215 million in revenue and $29 million adjusted EBITDA, but management explicitly pulled the majority of U.S. federal purchases out of Q4 guidance because the government ...
- Q3 revenue $215 million, up 2% year over year; year to date revenue up 6% vs 2024.
- Third quarter non-GAAP gross margin 52.6%, up 50 basis points sequentially, but lower than guided due to weaker software sales to U.S. government customers.
- Adjusted EBITDA was $29 million in Q3, down $1 million versus prior year; non-GAAP diluted EPS reported at $0.04.
- +12 more takeaways
Goosehead Insurance Q3 2025 Earnings Call - Aggressive tech bet to break the human capital bottleneck and scale premium growth
Goosehead reported another quarter of profitable growth while making a clear strategic pivot: double down on the digital agent to push past a longstanding human capital limit. Q3 results showed health...
- Q3 2025 results: total revenue $90.4 million, core revenue $83.9 million, adjusted EBITDA $29.7 million, adjusted EBITDA margin 33%.
- Total written premium in Q3 was $1.2 billion, up 15% year over year; franchise premiums $976 million (up 18%), corporate premiums $206 million (up 1%).
- Policies in force reached 1.9 million, up 13% year over year; franchise producers were 2,124, up 1% YoY, with producers per franchise at 2, up 6% YoY.
- +12 more takeaways
Las Vegas Sands Q3 2025 Earnings Call - Marina Bay Sands Momentum and Smart-Table Baccarat Are Rewriting the P&L
Marina Bay Sands powered a blowout quarter, delivering $743 million of EBITDA and pushing year-to-date MBS EBITDA north of $2.1 billion, with management now forecasting they will comfortably exceed th...
- Marina Bay Sands (MBS) reported Q3 EBITDA of $743 million and a margin of 51.7%, with year-to-date MBS EBITDA exceeding $2.1 billion and management expecting to surpass their $2.5 billion annual target for the asset in 2025.
- MBS slot win set a record at $905 million, up 122% versus Q3 2019 and 35% year-over-year, underscoring broad-based strength beyond tables.
- Smart-table technology has enabled precise measurement of rolling Baccarat behavior; measured theoretical hold for rolling/Baccarat in Singapore is now ~4.1%-4.2%, versus the long-standing ~2.85% baseline.
- +12 more takeaways
Kinder Morgan Q3 2025 Earnings Call - LNG and AI Power Demand Lock in Pipeline Growth
Kinder Morgan leaned hard into a familiar thesis, saying LNG export growth and rising 24/7 power demand from AI data centers make natural gas the structural winner for the next decade. The quarter del...
- KMI reported Q3 2025 EBITDA up 6% and adjusted EPS up 16% year over year, with GAAP net income attributable to KMI of $628 million and EPS of $0.28, in line with last year after stripping one-time items.
- Management doubled down on the long-term natural gas demand thesis, naming two drivers: explosive LNG export feed gas growth and 24/7 power demand from AI data centers that batteries and renewables alone cannot reliably serve.
- The company says industry consensus expects at least a doubling of LNG feed gas demand by 2030, citing S&P Commodity Insights estimating roughly 130% growth to about 31 to 32 Bcf per day.
- +12 more takeaways
Viking Therapeutics Q3 2025 Earnings Call - Oral VK2735 Delivers Strong Weight Loss, Sparks Maintenance and Phase‑3 Push
Viking used Q3 to convert clinical promise into momentum. Oral VK2735 posted robust phase 2 topline results — double-digit mean weight loss at 13 weeks with a clean tolerability profile — and the comp...
- Venture Oral Dosing Study (phase 2 tablet) met primary and secondary endpoints: up to 12.2% mean body‑weight reduction at 13 weeks for oral VK2735 versus placebo.
- Efficacy signal was rapid and dose‑responsive: statistically significant reductions versus placebo observed for all doses >15 mg starting at week 1 and persisting through week 13.
- High categorical responder rates in phase 2: up to 97% of VK2735 subjects achieved ≥5% weight loss, and up to 80% achieved ≥10%, versus 10% and 5% for placebo respectively.
- +13 more takeaways